Apellis Pharmaceuticals
(NASDAQ) APLS
Apellis Pharmaceuticals Financials at a Glance
Market Cap
$2.30B
Revenue (TTM)
$1.00B
Net Income (TTM)
$22.39M
EPS (TTM)
$0.12
P/E Ratio
145.51
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$17.96
Volume
56
Open
$17.84
Price
$17.96
Volume
56
Open
$17.84
Previous Close
$17.96
Daily Range
$17.59 - $18.00
52-Week Range
$16.10 - $30.48
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$17.96
Volume
56
Open
$17.84
Previous Close
$17.96
Daily Range
$17.59 - $18.00
52-Week Range
$16.10 - $30.48
APLS News
APLS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Apellis Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
739
CEO
Cedric Francois, MD, PhD
Website
www.apellis.comHeadquarters
Waltham, MA 02451, US
APLS Financials
Key Financial Metrics (TTM)
Gross Margin
90%
Operating Margin
6%
Net Income Margin
2%
Return on Equity
7%
Return on Capital
7%
Return on Assets
2%
Earnings Yield
0.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.30B
Shares Outstanding
127.83M
Volume
56
Short Interest
0.00%
Avg. Volume
2.72M
Financials (TTM)
Gross Profit
$901.55M
Operating Income
$55.43M
EBITDA
$70.00M
Operating Cash Flow
$45.33M
Capital Expenditure
$313.00K
Free Cash Flow
$45.01M
Cash & ST Invst.
$467.76M
Total Debt
$486.31M
Apellis Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$199.91M
-5.9%
Gross Profit
$170.19M
-0.9%
Gross Margin
85.13%
N/A
Market Cap
$2.30B
N/A
Market Cap/Employee
$3.26M
N/A
Employees
705
N/A
Net Income
$58.95M
-62.2%
EBITDA
$47.46M
-97.1%
Quarterly Fundamentals
Net Cash
$18.55M
+65.4%
Accounts Receivable
$366.22M
+34.8%
Inventory
$142.56M
+72.8%
Long Term Debt
$385.56M
-16.7%
Short Term Debt
$100.75M
+1391.9%
Return on Assets
2.08%
N/A
Return on Invested Capital
7.37%
N/A
Free Cash Flow
$13.97M
-172.2%
Operating Cash Flow
$14.18M
-173.2%